These two drugs are Keytruda from Merck (known as MSD outside the United States), an anticancer drug already central to the American giant's treatment portfolio, and Lifyorli from Corcept, also based in the United States. Two independent studies evaluated the effectiveness of these drugs against difficult-to-treat forms of breast cancer.ovary.
This remains one of the deadliest cancers affecting women. According to figures from the American Cancer Society, approximately half of women die within five years of diagnosis, which is often made when the cancer has already metastasized. One of the difficulties in treating this cancer stems from the fact that it often becomes resistant to the main treatment currently in use, platinum-based chemotherapy.
An increased survival rate of approximately four months
The studies therefore assessed whether the KeytrudaKeytruda, on the one hand, and Lifyorli, on the other, improved the situation for patients who continued their usual treatment. The two studies yielded similar results, although they cannot be directly compared due to methodological differences. Patients who received Keytruda or Lifyorli in addition to their usual treatment saw their survival increase by approximately four months on average.
Already approved by the USA and the EU
In any case, these two drugs have already been approved earlier this year by the United States and the European Union (EU) for the treatment of platinum-resistant ovarian cancer.
English 
French